Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 121Melanoma 111Neoplasms 66Carcinoma, Renal Cell 60Colorectal Neoplasms 43Neoplasm Metastasis 39Squamous Cell Carcinoma of Head and Neck 36Stomach Neoplasms 35Carcinoma, Hepatocellular 33Carcinoma, Transitional Cell 27Lung Neoplasms 23Pancreatic Neoplasms 22Triple Negative Breast Neoplasms 21Ovarian Neoplasms 21Head and Neck Neoplasms 21Advanced Cancer 19Breast Neoplasms 17Urinary Bladder Neoplasms 15Small Cell Lung Carcinoma 14Kidney Neoplasms 13Recurrence 11Hodgkin Disease 11Uterine Cervical Neoplasms 10Skin Neoplasms 10Lymphoma 10Solid Tumor 9Mesothelioma 9Endometrial Neoplasms 9Carcinoma, Merkel Cell 9Carcinoma 9

Interventions

pembrolizumab 2napabucasin 1Quality of Life 1Patient Reported Outcome Measures 1Paclitaxel 1Nivolumab 1Molecular Diagnostic Techniques 1Immunotherapy 1Drug Therapy 1Biological Therapy 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Thymus Neoplasms × Nivolumab × Clear all
NCT03447470 2025-01-29

Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies

Redx Pharma Ltd

Phase 1 Completed
46 enrolled 29 charts
Gastrointestinal

Biliary Tract Neoplasms, Neoplasms, Thymus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡